国新健康(000503) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥47,915,544.20, a decrease of 14.08% compared to ¥55,766,199.77 in the same period last year[6] - The net loss attributable to shareholders for Q1 2024 was ¥40,381,786.35, improving by 7.94% from a loss of ¥43,865,115.01 in the previous year[6] - Total operating revenue for Q1 2024 was CNY 47,915,544.20, a decrease of 14.1% from CNY 55,766,199.77 in the same period last year[26] - Net profit for Q1 2024 was a loss of CNY 40,380,236.63, compared to a loss of CNY 43,866,780.96 in Q1 2023, showing an improvement of 11.5%[26] - The total comprehensive income attributable to the parent company was -40,357,257.21 yuan, compared to -44,123,617.64 yuan in the previous period, showing an improvement of approximately 1.55%[29] - Basic and diluted earnings per share were both -0.0412 yuan, compared to -0.0484 yuan in the previous period, indicating a reduction in losses[29] Cash Flow and Liquidity - The net cash flow from operating activities was -¥100,443,543.19, a decline of 20.29% compared to -¥83,500,999.68 in the same period last year[6] - Cash inflows from operating activities totaled 36,827,535.37 yuan, down 24.4% from 48,705,936.60 yuan in the previous period[29] - Cash outflows from operating activities amounted to 137,271,078.56 yuan, slightly increased from 132,206,936.28 yuan in the previous period[29] - The net cash flow from operating activities was -100,443,543.19 yuan, worsening from -83,500,999.68 yuan in the previous period[29] - Cash outflows for investing activities were 10,932,550.06 yuan, up from 8,420,509.07 yuan in the previous period, reflecting increased investment[31] - Cash inflows from financing activities were 110,000,000.00 yuan, doubling from 55,000,000.00 yuan in the previous period, indicating strong financing efforts[31] - The net cash flow from financing activities was 12,875,276.95 yuan, a decrease from 43,866,996.67 yuan in the previous period[31] - The ending balance of cash and cash equivalents was 816,969,617.12 yuan, down from 915,460,540.32 yuan at the beginning of the period[31] - The company experienced a foreign exchange impact of 9,893.10 yuan on cash and cash equivalents, contrasting with a negative impact of -482,140.65 yuan in the previous period[31] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,892,159,936.71, down 3.04% from ¥1,951,543,466.24 at the end of the previous year[6] - The total liabilities decreased to CNY 510,843,074.10 from CNY 530,199,127.89, reflecting a reduction of approximately 3.5%[24] - The company's total current assets decreased to ¥1,524,653,215.13 from ¥1,590,196,930.31, reflecting a reduction of 4.14%[1] Investments and Income - The company reported a significant increase in investment income, which rose by 312.33% to ¥1,382,398.95 from ¥335,268.91, attributed to the profit growth of joint ventures[7] - The company reported an investment income of CNY 1,382,398.95 in Q1 2024, compared to CNY 335,268.91 in the previous year, indicating a substantial increase[26] Shareholder Information - The total number of common shareholders at the end of the reporting period was 49,270[10] - The largest shareholder, China Oceanwide Holdings Group Co., Ltd., holds 23.95% of shares, totaling 235,702,593 shares[10] - The second largest shareholder, Guoxin Development Investment Management Co., Ltd., holds 2.45% of shares, totaling 24,123,980 shares[10] - The top ten shareholders include both state-owned and foreign entities, with the largest foreign shareholder holding 1.94%[10] - The report indicates that there are no known relationships among other circulating shareholders[11] - The company has not disclosed any changes in the top ten shareholders due to securities lending activities[12] - The report does not indicate any significant changes in the shareholding structure compared to the previous period[12] Operational Efficiency - Management expenses decreased by 30.43% to ¥22,052,798.58 from ¥31,696,816.76 due to optimization of personnel structure[7] - Research and development expenses were CNY 0.00 in Q1 2024, significantly down from CNY 967,945.83 in Q1 2023[26] Future Plans - The company plans to use RMB 413.947 million of raised funds to replace pre-invested self-raised funds for project implementation[16] - The company will utilize up to RMB 350 million of temporarily idle raised funds for cash management[17] - The company plans to enhance its market presence and explore new strategies for growth, although specific details were not disclosed in the report[28] Contract and Inventory Management - The balance of contract assets increased by 37.34% to ¥86,924,784.08 from ¥63,289,805.63 due to progress in contract execution[7] - The inventory balance rose by 93.71% to ¥3,948,710.95 from ¥2,038,468.28, driven by increased procurement related to business demand[7]